SK Biopharm said on the 10th that it received the top AAA rating in this year's ESG assessment announced by Morgan Stanley Capital International (MSCI), a global ESG (environment, society, and governance) ratings agency.
SK Biopharm remained at AAA for the second straight year, the only domestic pharmaceutical company included in the global AAA group. MSCI conducts a comprehensive assessment of ESG management each year for about 8,500 listed companies worldwide. Of the 203 pharmaceutical companies evaluated this year, only six (about 3%) received AAA.
Some large global pharmaceutical companies were downgraded, but SK Biopharm rose in rank from the previous year to place fourth among global drugmakers that received AAA. It was reported to have earned high marks in core areas such as human capital management, ethical management, and quality and safety management.
President Lee Dong-hoon of SK Biopharm said, "We maintained the AAA rating for two consecutive years as the only domestic corporations in a strengthened global ESG assessment environment," and added, "As a global new drug development company, we will fulfill our social responsibility and provide sustainable value to patients and society."